EA
SCLN

Emerald Acquisition’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Emerald Acquisition’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$873K Buy
85,139
+25,527
+43% +$278K ﹤0.01% 2201
2016
Q2 		$779K Buy
+59,612
New +$781K ﹤0.01% 2291

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Emerald Acquisition's SCLN Position: Q3 2016 in Review

Emerald Acquisition increased its Sciclone Pharmaceuticals Inc (SCLN) stake by 43% in Q3 2016, buying an estimated $278K and bringing the position to 85,139 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Emerald Acquisition first reported a position in SCLN in Q2 2016 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Emerald Acquisition held 85,139 shares of Sciclone Pharmaceuticals Inc worth $873K as of Q3 2016.
  • Emerald Acquisition bought 25,527 Sciclone Pharmaceuticals Inc shares in Q3 2016, an estimated $278K.
  • Sciclone Pharmaceuticals Inc made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2201 holding.
  • Emerald Acquisition first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.